Nonetheless, the here described subclass specific targeting opens the chance to specifically redirect CD8+ T cells in cancer patients either by adoptive transfer of ex vivo activated CD8+ T cells combined with CD8-engaging bsAb treatment or by application of a CD8-directed bsAb in combination with IL-2 treatment. The gene discussed is IL2; the disease is cancer.